Posts Tagged ‘Featured’
Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA
Lancet. 2023 Nov 15:S0140-6736(23)01683-5. Online ahead of print. PMID: 37979595 | DOI: 10.1016/S0140-6736(23)01683-5
Read MoreCGRP signalling in migraine: time to look downstream?
Brain. 2023 Nov 16:awad390. Online ahead of print. PMID: 37972256 | DOI: 10.1093/brain/awad390
Read MoreThe pipeline and market for migraine drugs
Nat Rev Drug Discov. 2023 Nov 17. Online ahead of print. PMID: 37978262 | DOI: 10.1038/d41573-023-00182-x
Read MoreReal-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study
Cephalalgia. 2023 Nov;43(11):3331024231214987. PMID: 37987641 | DOI: 10.1177/03331024231214987
Read MoreA prospective open label 2-8 year extension of the randomised controlled ICON trial on the long-term efficacy and safety of occipital nerve stimulation in medically intractable chronic cluster headache
EBioMedicine. 2023 Nov 25;98:104895. Online ahead of print. PMID: 38007947 | DOI: 10.1016/j.ebiom.2023.104895
Read MoreHypersensitivity to opening of ATP-sensitive potassium channels in post-traumatic headache
Cephalalgia. 2023 Nov;43(11):3331024231210930. PMID: 37917826 | DOI: 10.1177/03331024231210930
Read MoreComparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial
Neurol Ther. 2023 Nov 10. Online ahead of print. PMID: 37948006 | DOI: 10.1007/s40120-023-00562-w
Read MoreXenobiotic Exposure and Migraine-Associated Signaling: A Multimethod Experimental Study Exploring Cellular Assays in Combination with Ex Vivo and In Vivo Mouse Models
Environ Health Perspect. 2023 Nov;131(11):117003. PMID: 37909725 | PMC: PMC10619430 | DOI: 10.1289/EHP12413
Read MoreShifting Attention from the Outside to the Inside of the Cell during Migraine
New research shows that second messenger signaling spurs migraine attacks even in the presence of CGRP receptor blockade.
Read MoreHypersensitivity to PACAP-38 in post-traumatic headache: a randomized clinical trial
Brain. 2023 Oct 21:awad367. Online ahead of print. PMID: 37864847 | DOI: 10.1093/brain/awad367
Read More